AI-powered digital twins is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Lawrence Berkeley National Laboratory (LBNL)
AI-powered digital twins is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. market-trends accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention Lawrence Berkeley National Laboratory (LBNL), all published on August 1, 2026.
Stories tracked
2
Sources per story
2
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Lawrence Berkeley National Laboratory (LBNL). Shared-story counts are live from our verified record — not editorial picks.
Publicly traded yet still aggressively scaling, eXoZymes gains validation and high-powered computing access through a DOE partnership. The 9-month digital twin project could act as a force multiplier, strengthening its tech moat and opening enterprise-level biomanufacturing deals.
eXoZymes lands a high-profile DOE grant to develop AI digital twins for cell-free enzyme manufacturing. The 9-month collaboration with Lawrence Berkeley Lab could slash process development timelines and unlock faster routes for nutraceuticals and novel therapeutics.